Novadaq Technologies Inc.TSX: NDQ

Novadaq Obtains Exclusive Nerve Imaging IP

· Issued by Novadaq Technologies Inc. via CNW
Potentially Reduces Side Effects in Prostate Surgery 

TORONTO, Feb. 8 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ) announced
today that it has signed an exclusive agreement with the University of
Rochester, Rochester, New York, to license a broad portfolio of patents in the
field of intra-operative fluorescence guided imaging of nerves, including
image guided conventional and minimally invasive nerve-sparing radical
prostatectomy. The agreement enables Novadaq to develop and globally
commercialize the resulting proprietary nerve imaging technologies.
"The research team at the University of Rochester Medical Center (URMC)
has been studying Novadaq's fluorescence imaging technology as a unique
approach to visualize nerves and we are extremely pleased to be partnering
with such an innovative team," said Dr. Arun Menawat, President and Chief
Executive Officer of Novadaq Technologies Inc. "We are confident that the
combination of this technology with our existing and commercially proven
SPY(R) System in cardiac surgery, will provide us an opportunity to lead the
way in medical imaging for urologic and other operating room procedures."
Prostate cancer affects more than 1.8 million men in the United States
alone. One in six will develop prostate cancer and more than a quarter of a
million new cases are diagnosed each year. Radical prostatectomy, involving
surgical removal of the entire prostate, is the most commonly prescribed
treatment for prostate cancer and is associated with excellent survival rates.
However, 50% of men undergoing radical prostatectomy will suffer erectile
dysfunction (ED) following the procedure due to inadvertent damage to the
nerve bundles located at either side of the prostate. The ability to image
these nerves during prostate surgery by combining the newly licensed
technologies and Novadaq's existing fluorescence imaging technology, currently
used to visualize arteries during cardiac surgery, may reduce nerve damage and
typical side effects and more significantly, the possibility of erectile
dysfunction.
"We are pleased to partner with Novadaq. The use of the same fluorescent
agent as with the current SPY System for cardiac surgery applications, has
allowed us to quickly and easily visualize nerves in the laboratory," said
Professor Edward M. Messing, M.D., Chairman, Department of Urology, University
of Rochester School of Medicine & Dentistry. "We now look forward to
researching the benefits of the SPY System in a clinical study."
"Although the survival rates associated with prostate surgery are
excellent, the side effects related to nerve damage during the procedure are
difficult for most men to live with," said Dr. Menawat. "Fluorescence image
guided nerve sparing prostatectomy will address a huge unmet need and has the
potential to significantly reduce impotence due to surgery and improve patient
quality of life."

About Novadaq Technologies

Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular, ophthalmic, and neurologic diseases and
conditions. Novadaq's SPY Intra-operative Imaging System, commercially
available worldwide, enables cardiac surgeons to visually assess coronary
vasculature and bypass graft functionality during the course of open-heart
bypass surgery. Novadaq's ophthalmic product, the OPTTX(TM) System, is aimed
at the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials.
For more information, please visit the company's website at
www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases